Search clinical trials for: Sitagliptin/metformin

Total 2748 results

Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)

Type 2 Diabetes
Shanghai Jiao Tong University School of Medicine

Unknown

Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp

Type 2 Diabetes

China
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)

Type 2 Diabetes Mellitus
Astellas Pharma Inc

Completed

A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Merck Sharp & Dohme LLC

Completed

MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Type 2 Diabetes Mellitus
Sanofi

Completed

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

Type 2 Diabetes Mellitus

Brazil, Peru, United States, Australia, Canada, Chile, Germany, Guatemala, Mexico, Poland, Romania, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Regimen Comparison Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431A-136)

Type 2 Diabetes Mellitus
Lin Liao

Unknown

Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin

Type 2 Diabetes Mellitus

China
Novartis Pharmaceuticals

Completed

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Korea, Republic of, Latvia, Peru, Lithuania, Israel, Norway, Finland, Argentina, Austria, Belgium, Germany, Greece, Guatemala, Hungary, India, Italy, Mexico, Poland, Romania, Slovakia, Venezuela
Woman's
AstraZeneca

Completed

Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis (BMS-AZPCOS)

Polycystic Ovary Syndrome | Disorder of Glucose Regulation

United States
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)

Type 2 Diabetes Mellitus
Rush University Medical Center

Withdrawn

Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit

Type 2 Diabetes Mellitus
Lund University

Completed

DPP-4 Inhibition, Incretins and Islet Function (CODI24)

Type 2 Diabetes

Sweden
GlaxoSmithKline

Completed

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States
AstraZeneca

Completed

Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation, Romania, Poland, Czech Republic, Puerto Rico, Hungary
Merck Sharp & Dohme LLC

Completed

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)

Type 2 Diabetes Mellitus
Institute of Liver and Biliary Sciences, India

Not yet recruiting

To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

Decompensated Cirrhosis | Compensated Cirrhosis

India
Merck Sharp & Dohme LLC

Completed

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Sanofi

Completed

Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial

Diabetes Mellitus, Type 2

United States, Brazil, Netherlands, Portugal, Spain, India, Austria, Egypt, Greece, Israel, Mexico, United Kingdom, Korea, Republic of, Hong Kong, Colombia, Lebanon
Sanofi

Completed

Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients (EASIE)

Diabetes Mellitus, Type 2

United States, Brazil, Netherlands, Portugal, Spain, Turkey, India, Austria, Egypt, Greece, Israel, Mexico, United Kingdom, Korea, Republic of, Hong Kong, Colombia, Lebanon
Assistance Publique Hopitaux De Marseille

Completed

Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

Obesity | Diabetes

France
AstraZeneca

Completed

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Type 2 Diabetes

United States
Assistance Publique - Hôpitaux de Paris

Recruiting

Impact of Metformin on Peripheral Arterial Calcification in Type 1 Diabetes (IMPACT-1D)

Type 1 Diabetes | Peripheral Arterial Calcification

France
Alexandria University

Recruiting

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS)

Egypt
University of Texas Southwestern Medical Center

Completed

Preservation of Beta-cell Function in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC

Completed

Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)

Type 2 Diabetes Mellitus (T2DM)
University of Dundee

Completed

Response To Oral Agents in Diabetes (ROAD)- Pilot Study (ROAD)

Diabetes Mellitus, Type 2

United Kingdom
Merck Sharp & Dohme LLC

Completed

An Observational Study of Type II Diabetics Treated With Dual Therapy With or Without Sitagliptin (Januvia®/Xelevia®, MK-0431-201)

Type 2 Diabetes Mellitus
AstraZeneca
Bristol-Myers Squibb

Completed

Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

Sweden, Bulgaria, Czech Republic, Hungary, Poland
Eli Lilly and Company

Terminated

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) (IMPERIUM)

Diabetes Mellitus, Type 2

United States, Puerto Rico, Germany, United Kingdom, Austria
Eli Lilly and Company
Berry Consultants; United BioSource, LLC; Tessella Inc.

Completed

A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin

Diabetes Mellitus, Type 2

United States, Korea, Republic of, Russian Federation, Puerto Rico, Romania, Spain, Taiwan, Mexico, France, Germany, India, Canada, Poland
Boehringer Ingelheim

Completed

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

Diabetes Mellitus, Type 2

United States, Austria, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Norway, Romania, Russian Federation, Slovakia, Spain, Sweden, Taiwan, Ukraine
Jothydev's Diabetes and Research Centre

Completed

Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin

Diabetes Mellitus, Type 2

India
Huashan Hospital

Recruiting

Research on Optimal Strategy of Hypoglycemic Therapy for Cirrhosis With Diabetes

Liver Cirrhosis | Diabetes

China
Novartis Pharmaceuticals

Completed

Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly

Acromegaly | Cushing's Disease

United States, Turkey, Belgium, Thailand, Germany, Denmark, Russian Federation, Peru, China, Brazil, India, Poland
Shanghai Zhongshan Hospital
Chinese Medical Association

Completed

Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

China
Theracos

Completed

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Type2 Diabetes Mellitus

United States
Taipei Veterans General Hospital, Taiwan

Unknown

ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia

Type 2 Diabetes

Taiwan
AstraZeneca
Bristol-Myers Squibb

Completed

An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes (SCORE)

Type 2 Diabetes

United States, Peru, Mexico, Colombia, Costa Rica
Merck Sharp & Dohme LLC

Completed

MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

Dose Response Finding Study of MK-0431/ONO-5435 in Japanese Subjects With Impaired Glucose Tolerance (MK-0431-105)

Glucose Intolerance
Merck Sharp & Dohme LLC

Completed

Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)

Type 2 Diabetes Mellitus
Hadassah Medical Organization

Unknown

Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy

Diabetes Mellitus | Iron Metabolism Disorders | Optic Atrophy | Sensorineural Hearing Loss | Platelet Dysfunction | Gastroduodenal Ulcer

Israel
Institut für Pharmakologie und Präventive Medizin
University of Erlangen-Nürnberg Medical School

Completed

Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes (ELMI)

Diabetes Mellitus Type 2

Germany

3

Subscribe